Ifinatamab Deruxtecan not checked
Daiichi Sankyo · DS-7300a · MK-2400
FollowEvery change as it happens, and a Monday email
Trials
13 active
13 in total · 11 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Administered via intravenous (IV) infusion every 3 weeks (q3w) until disease progression, unacceptable adverse events (AEs), or other cessation of treatment”In the company’s words, NCT06925737 on ClinicalTrials.gov
- Tested for
- Small Cell Lung Cancer (2 trials), Carcinoma, Non-Small-Cell Lung (2 trials), Esophageal Squamous Cell Carcinoma, Prostate Cancer, Prostatic Neoplasms, Extensive-stage Small-cell Lung Cancer, Advanced Solid Tumor, Malignant Solid Tumor and 7 more
- Main trialPhase 3
- “This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).”In the company’s words, NCT06203210 on ClinicalTrials.gov
- Other names
- DS-7300a · MK-2400 · I-DXd
Other drugs for Small Cell Lung Cancer
- PembrolizumabMerck & Co. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Tambotatug pelitecanMediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- ZG006Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3
Coming up12
- 30 Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 20 Jul 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 28 Jan 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Jan 2028Phase 3 trial completes · ClinicalTrials.gov
- 1 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 26 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 25 Jul 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 15 Feb 2029Phase 1/2 trial completes · ClinicalTrials.gov
- 17 Aug 2031Phase 1/2 trial completes · ClinicalTrials.gov
- 1 Oct 2031Phase 1/2 trial completes · ClinicalTrials.gov
- 13 Feb 2032Phase 1/2 trial completes · ClinicalTrials.gov
- 12 Mar 2032Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Jan 2028 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | |
| Phase 3Recruiting | 1 Jun 2028 | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | |
| Phase 3Recruiting | 26 Jun 2028 | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | |
| Phase 2Active, not recruiting | 3 Mar 2025 | Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | |
| Phase 2Active, not recruiting | 12 Mar 2032 | A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) | |
| Phase 1/2Active, not recruiting | 30 Apr 2027 | Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | |
| Phase 1/2Recruiting | 20 Jul 2027 | A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | |
| Phase 1/2Active, not recruiting | 28 Jan 2028 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | |
| Phase 1/2Recruiting | 25 Jul 2028 | A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) | |
| Phase 1/2Recruiting | 15 Feb 2029 | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | |
| Phase 1/2Recruiting | 17 Aug 2031 | A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) | |
| Phase 1/2Recruiting | 1 Oct 2031 | A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) | |
| Phase 1/2Recruiting | 13 Feb 2032 | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026